Preclinical pharmacology – cardiovascular efficacy and safety R&D
The development of new drugs to improve the quality of human life is all about managing risk, achieving performance milestones and maximising the value of technology. There is a need to ensure that the safety profile of every candidate product is as good as the performance of the drug in the intended medical application. The Cardiovascular Therapeutics Unit can assist in the early safety testing of pharmaceutical candidates from the R&D portfolios of Biotech or Big Pharma companies. The Cardiovascular Therapeutics Unit specialises in the cardiovascular pharmacological assessment of candidate pharmaceutical compounds. The Unit has extensive experience in non-GLP studies to assist in the selection of lead drug candidates or in focusing medicinal chemistry strategies to minimise the risks of unexpected cardiac toxicity.
Studies will be completed in a timely manner with full confidentiality. Please contact the laboratory head for further information or study costs.
The range of experimental preparations includes:
- In vitro myograph small resistance blood vessels
- Isolated atrial & papillary muscles & vascular tissues
- In vivo experimental animal haemodynamic assessment & QTc analysis
- Preparations of chronic cardiovascular disease such as hypertension & vascular injury
Professor James A. Angus, AO, BSc Hons, PhD, FAA, FAHMS (Hon),
Mr Mark Ross-Smith, BSc Hons, Senior Research Assistant
Ms Linda Cornthwaite-Duncan, Technical Officer
- Wright CE, Angus JA. Techniques to measure pharmacodynamics in the intact vasculature. J Pharmacol Toxicol Meth 2000; 44: 385-394.
- Angus JA, Wright CE. Techniques to study the pharmacodynamics of isolated large and small blood vessels. J Pharmacol Toxicol Meth 2000; 44: 395-407.
- Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH. PI 3-kinase p110b: a new target for antithrombotic therapy. Nature Med 2005; 11: 507-514.
- Angus JA, Soeding PF, Hughes RJA, Wright CE. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro. Eur J Pharmacol 2017; 804: 111-116.
School Research Themes
For further information about this research, please contact the research group leader.